Dapagliflozin for advanced heart failure patients waiting for transplant
Part of Heart & circulation clinical trials.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 to 85 years old
- Severe heart failure symptoms (NYHA class III or IV) – meaning shortness of breath or fatigue even with minimal activity or at rest
- Heart's pumping strength (LVEF) is 35% or less
- Already on standard heart failure treatments, including dapagliflozin, at the highest tolerated doses
- On the waiting list for a heart transplant (or on the path to be listed), with no expected transplant in the next 6 months
- No current use of a heart pump (VAD), no dependence on IV heart medicines, and no recent hospital stay for worsening heart failure in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.